Medpace earnings exceeded analyst expectations in the third quarter of 2026, with GAAP diluted earnings per share of $4.84 against an estimated $4.44. Revenue increased 8.5% to $716.0 million. The company filed its 8-K on October 21, 2026.
Key Takeaways
- GAAP net income rose to $137.5 million from $111.1 million a year earlier.
- Net income margin expanded to 19.2%, while EBITDA margin increased to 24.0%.
- Net new business awards grew 10.6% to $873.4 million.
Table of Contents
- Medpace earnings growth outpaces revenue
- Profit margins widen on higher sales
- New business awards add to year-to-date growth
- Conclusion
Medpace earnings growth outpaces revenue
The clinical contract research organization reported higher quarterly profit alongside a smaller percentage increase in sales. Revenue rose from $659.9 million in the third quarter of 2025, while GAAP net income increased from $111.1 million to $137.5 million.
Diluted earnings per share climbed from $3.86 a year earlier to $4.84. The reported result was $0.40 above the analyst estimate.
Based in Cincinnati, Ohio, Medpace provides clinical development services to pharmaceutical and biotechnology businesses, with a focus on mid-sized biopharmaceutical companies and phases I through IV of clinical trials.
Profit margins widen on higher sales
Net income margin reached 19.2%, compared with 16.8% in the prior-year quarter. EBITDA increased to $172.1 million from $148.4 million, with EBITDA margin rising to 24.0% from 22.5%.
Those figures show profitability improving alongside revenue growth. The company also recorded a backlog conversion rate of 23.8%, a measure of its conversion of previously secured work into revenue.
New business awards add to year-to-date growth
Net new business awards totaled $873.4 million, up 10.6% from $789.6 million a year earlier. That increase accompanied continued expansion in revenue across the year to date.
Year-to-date revenue reached $2.129 billion, an increase of 16.9% from $1.822 billion in the comparable 2025 period. The year-to-date growth rate was higher than the 8.5% increase reported for the third quarter alone.
Conclusion
Medpace’s third-quarter results combined an earnings beat with higher revenue, wider margins and increased new business awards. Year-to-date revenue growth remained ahead of the pace recorded in the latest quarter.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
